[go: up one dir, main page]

SE1500434A1 - A novel fusion partner for highly efficient and safe vaccines - Google Patents

A novel fusion partner for highly efficient and safe vaccines Download PDF

Info

Publication number
SE1500434A1
SE1500434A1 SE1500434A SE1500434A SE1500434A1 SE 1500434 A1 SE1500434 A1 SE 1500434A1 SE 1500434 A SE1500434 A SE 1500434A SE 1500434 A SE1500434 A SE 1500434A SE 1500434 A1 SE1500434 A1 SE 1500434A1
Authority
SE
Sweden
Prior art keywords
fusion partner
vaccine composition
original
composition according
proteins
Prior art date
Application number
SE1500434A
Other languages
Swedish (sv)
Inventor
Hellman Lars
Olsson Anna-Karin
Saupe Falk
Original Assignee
Theravac Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravac Pharmaceuticals Ab filed Critical Theravac Pharmaceuticals Ab
Priority to SE1500434A priority Critical patent/SE1500434A1/en
Priority to PCT/SE2016/000056 priority patent/WO2017074235A1/en
Publication of SE1500434A1 publication Critical patent/SE1500434A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to the use of the C terminal region of Lamprey or Hagfish variable leukocyte receptor (VLR) as fusion partner in various vaccine antigens to be used in therapeutic or preventive vaccine formulations for the treatment of inflammatory, autoimmune conditions or cancer.

Claims (7)

1. A Vaccine composition stimulating the immune system to induce a strong therapeutic or preVentiVeantibody response against any therapeutic target self-antigen or -protein and containing the targetantigen, or a part or fragment thereof, being fused to a fusion partner, and optionally apharmaceutically acceptable adjuVant, characterized in that the fusion partner is the C terminalpentamerizing (multimerizing) region of the hagfish or lamprey Variable leukocyte receptor B (VLR-B), in its original or mutated form.
2. A Vaccine composition according to claim 1 for therapeutic or preVentiVe treatment of cancertumors, allergic inflammation, autoimmune disorders or other inflammatory conditions.
3. A Vaccine composition according to claim 1 or 2, characterized in that it is directed against self-proteins expressed in and around tumor Vessels and containing a single or a combination of the aminoacid sequences of the extra domain B of fibronectin (EDB), the extra domain A of fibronectin (EDA)or the extra domain C of tenascin C or at least one fragment thereof, in its original or multimerizedform, coupled to the fusion partner.
4. A Vaccine composition according to claim 1 or 2, characterized in that it is directed against self-proteins acting as immunosupressants in treating tumors and containing the proangiogenic andimmunosuppressiVe protein galectin-1 or at least one fragment thereof, in its original or multimerizedform, coupled to the fusion partner.
5. A Vaccine composition according to claim 1 or 2, characterized in that is directed against self-proteins acting as early regulators of inflammatory conditions and containing a single or combinationsof the cytokines IL-SS, 11-31, IL-18, IL-17 and thymic stromal lymphopoietin (TSLP) or at least onefragment thereof, in its original or multimerized form, coupled to the fusion partner.
6. A fusion partner to generate a Vaccine antigen to target Various self-proteins in a preVentiVe ortherapeutic Vaccine composition according to any of claims 1-5, characterized by being the the Cterminal pentamerizing (multimerizing) region of the hagfish or lamprey Variable leukocyte receptor B(VLR-B), in its original or mutated form.
7. The use of a fusion partner according to claim 6, being the C terminal pentamerizing(multimerizing) region of the hagfish or lamprey Variable leukocyte receptor B (VLR-B), in itsoriginal or mutated form, as a fusion partner to generate a Vaccine antigen to target Various self-proteins in a preVentiVe or therapeutic Vaccine.
SE1500434A 2015-10-29 2015-10-29 A novel fusion partner for highly efficient and safe vaccines SE1500434A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE1500434A SE1500434A1 (en) 2015-10-29 2015-10-29 A novel fusion partner for highly efficient and safe vaccines
PCT/SE2016/000056 WO2017074235A1 (en) 2015-10-29 2016-10-12 A novel fusion partner for safe vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1500434A SE1500434A1 (en) 2015-10-29 2015-10-29 A novel fusion partner for highly efficient and safe vaccines

Publications (1)

Publication Number Publication Date
SE1500434A1 true SE1500434A1 (en) 2017-04-30

Family

ID=58631989

Family Applications (1)

Application Number Title Priority Date Filing Date
SE1500434A SE1500434A1 (en) 2015-10-29 2015-10-29 A novel fusion partner for highly efficient and safe vaccines

Country Status (2)

Country Link
SE (1) SE1500434A1 (en)
WO (1) WO2017074235A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101972894B1 (en) * 2017-05-18 2019-04-29 경상대학교산학협력단 Fusion protein comprising C-terminus from lamprey VLRB protein linked to hagfish VLRB protein with deleted hydrophobic tail domain and uses thereof
US20220347261A1 (en) * 2021-04-23 2022-11-03 Vlp Therapeutics, Inc. Galectin-targeting immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574473A (en) * 2006-08-02 2013-02-22 Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
KR20120107741A (en) * 2011-03-22 2012-10-04 한국생명공학연구원 Method for screening protein therapeutics for sepsis treatment
CA2947429A1 (en) * 2014-05-02 2015-11-05 Emory University Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto
US10118951B2 (en) * 2014-12-19 2018-11-06 Sanofi Pasteur Multimerization of recombinant protein by fusion to a sequence from lamprey

Also Published As

Publication number Publication date
WO2017074235A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
MX2016010174A (en) Interleukine 10 immunoconjugates.
MX2019014695A (en) Interleukin-2 fusion proteins and uses thereof.
MX2020001996A (en) Anti-cd137 molecules and use thereof.
PH12020500670A1 (en) Molecular adjuvant
MX2021008796A (en) Antibodies against il-7r alpha subunit and uses thereof.
AU2018282094A1 (en) Antibodies that specifically bind PD-1 and methods of use
PH12018500098A1 (en) Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
HK1231487A1 (en) Antibodies directed against cd127
EP4406610A3 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
PH12013500990A1 (en) Neutralizing anti-ccl20 antibodies
MX2018004598A (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy.
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
MX2017004897A (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy.
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
CA3011786C (en) Anti-tnf.alpha.-antibodies and functional fragments thereof
WO2015161267A3 (en) Humanized and chimeric monoclonal antibodies to cd99
CY1122061T1 (en) CHIMERIC SOLUBLE INTERLEUKIN-10 RECEPTOR AND THERAPEUTIC USE THEREOF
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
ZA202006216B (en) Antibodies targeting glycoprotein vi
WO2020079448A9 (en) Novel cancer antigens and methods
SE1500434A1 (en) A novel fusion partner for highly efficient and safe vaccines
MY197821A (en) Anti-il-22r antibodies
MX2022004086A (en) Anti-tigit antibodies and uses thereof.

Legal Events

Date Code Title Description
NAV Patent application has lapsed